SLN7:30 AMSilence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Verasilence-therapeutics.com
SLN8:00 AMSilence Therapeutics to Participate in Jefferies Global Healthcare Conferencesilence-therapeutics.com
SLN8:00 AMSilence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conferencesilence-therapeutics.com
SLN8:00 AMSilence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Resultssilence-therapeutics.com